CLIA Thyrotropin Receptor Antibody TRAb IVD Products for Chemiluminescent Immunoassay in Thyroid

TRAb detection kit (CLIA) (hereinafter referred to as the kit) is  used for the in vitro quantitative determination of  TRAbconcentration in human serum, which is mainly for diagnosis of Graves disease. TRAb is a kind of IgGsecreted by lymphocytes, and its corresponding antigen is the membrane surface part of thyroid  cells near TSH receptor.When TRAb binds with the thyroid cells,  it will be activated; resulting in thyroid function is stimulated,  causing hyperthyroidism and goiter.Its role resembles TSH. It is  not controlled by the negative feedback control system, which  results in clinical symptoms of hyperthyroidism of Graves’s  disease. 

TRAb indications include: 1. Autoimmune hyperthyroidism  diagnosis and troubleshooting, as well as multi-functional  autonomous thyroid nodular goiter. Because Graves disease  treatment different from other treatment of hyperthyroidism, so  the initial TRAb measurement is very useful. 2. Monitoring  Graves' disease treatment and recurrences, and has important  significance for clinical management. Graves disease during  treatment with antithyroid drugs often TRAb concentration  decreased after medical treatment TRAb low concentration or  disappearance may indicate remission, termination of treatment  may be considered. 3. TRAb measured the last three months of  pregnancy. As TRAb is IgG antibody, it can be transferredthrough  the placenta and cause neonatal thyroid disease. Therefore, it is  very important for the patients with a history of thyroid disease  during pregnancy to test TRAb which can determine the risk  degree of neonatal thyroid disease.